Financial Analysis: Genelux (NASDAQ:GNLX) & Bullfrog AI (NASDAQ:BFRG)

Genelux (NASDAQ:GNLX) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Insider and Institutional Ownership

37.3% of Genelux shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 9.3% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Genelux and Bullfrog AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-125.58%	-86.03%
Bullfrog AI	N/A	-131.39%	-114.76%

Valuation & Earnings

This table compares Genelux and Bullfrog AI’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$170,000.00	434.43	-$28.30 million	($0.97)	-2.22
Bullfrog AI	$60,000.00	226.34	-$5.36 million	($0.88)	-1.97

Bullfrog AI has lower revenue, but higher earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Genelux has a beta of -1.37, indicating that its stock price is 237% less volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Genelux and Bullfrog AI, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	0	0	4	0	3.00
Bullfrog AI	0	0	0	0	N/A

Genelux currently has a consensus price target of $32.33, indicating a potential upside of 1,403.88%. Given Genelux’s higher possible upside, analysts plainly believe Genelux is more favorable than Bullfrog AI.

Summary

Genelux beats Bullfrog AI on 8 of the 12 factors compared between the two stocks.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.